Secondly, BMS sealed a major deal with Nektar last week on a next generation immunotherapy NKTR-214, a move which Baum believes could materially increase Opdivo's market share.

We find that Braemar’s ratio of 14.61x is trading slightly above its industry peers’ ratio of 14.5x, which means if you buy Braemar today, you’d be paying a relatively sensible price for it. And if ...

Bristol Myers Squibb has exercised an option on an immune-modulating drug candidate developed by UK artificial intelligence specialist Exscientia, paying $20 million for the buy-in as part of ...

Insure your 2015 BMS Motorsports for just $75/year.* Savings: We offer low rates and plenty of discounts. More riding freedom: Your UTV is covered in and off your property. OEM parts in repairs: We ...